Stem Pharm announced recently that it has been awarded a Small Business Innovation Research (SBIR)
grant from the National Institutes of Health (NIH) to advance a groundbreaking model of Alzheimer’s Disease (AD) for drug discovery.

“We are honored and excited to receive this SBIR grant from the NIH, which recognizes the potential impact of our work in advancing Alzheimer’s Disease research,” CEO Dr. Steven Visuri said in a statement. “This funding will allow us to make significant strides in our mission to develop innovative treatments that can change the lives of those affected by neurologic diseases.”

In addition, Stem Pharm announced it is collaborating with Verge Genomics to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease.

“We are incredibly excited to partner with Verge to apply our neuro-immune organoid platform to Parkinson’s disease,” Dr. Visuri said. “Verge’s all-in-human approach to drug discovery aligns perfectly with our ideology, and by combining our strengths and resources, we aim to establish a state-of-the-art Parkinson’s disease model. This collaboration represents a significant step forward in our collective mission to discover transformative therapies for patients suffering from this debilitating disease.”

Financial terms were not disclosed in either announcement.